Case Report: Apparent progressive complete mismatch repair protein loss during platinum-based chemotherapy in metastatic rectal neuroendocrine tumour grade 2.

Authors

Yue Yang, Gao Li, Jinghui Wang, Wenyu Wu, Dongxin Tang

Published in

Frontiers in oncology. Volume 16. Pages 1885566. Epub Sep 28, 2026.

Abstract

Mismatch repair (MMR) deficiency is uncommon in gastroenteropancreatic neuroendocrine tumours (GEP-NETs), yet it represents a critical biomarker for immune checkpoint inhibitor (ICI) eligibility. Treatment-associated reduction or loss of MMR protein expression, often without corresponding MSI-H, has been reported in colorectal adenocarcinoma, but comparable changes have not been described in neuroendocrine tumours. Persistent discordance between immunohistochemistry (IHC)-based MMR protein assessment and next-generation sequencing (NGS)-based microsatellite instability (MSI) testing is an emerging and clinically challenging phenomenon.
We report a 55-year-old woman initially diagnosed with rectal NET Grade 1 on endoscopic biopsy; the tumour was upgraded to NET Grade 2 (Ki-67 approximately 20%) on the surgical resectionk specimen. Hepatic metastases were confirmed four months after resection. The first liver biopsy (January 16, 2026) demonstrated partial MMR protein loss by IHC (MLH1-, MSH2+, MSH6-, PMS2-), while concurrent NGS showed microsatellite stability (MSS) and a tumour mutational burden (TMB) of <1 mut/Mb. The patient received two cycles of surufatinib 250 mg orally once daily combined with intravenous carboplatin (500 mg, day 1) and etoposide (160 mg, days 1-3). Restaging CT demonstrated disease progression. A repeat liver biopsy (March 17, 2026) revealed complete loss of all four MMR proteins by IHC (MLH1-, MSH2-, MSH6-, PMS2-), while NGS again confirmed MSS and TMB <1 mut/Mb.
To the best of our knowledge, this is the first reported case of apparent progressive complete MMR protein loss in the context of sequential platinum-based chemotherapy in metastatic rectal NET Grade 2, with persistent IHC-NGS discordance throughout. These findings raise an important question regarding how IHC-defined dMMR should be interpreted in the absence of NGS-confirmed MSI-H, and highlight the complexity of immunotherapy eligibility decisions in rare tumour types. Prospective data are needed to guide clinical practice.

PMID:
42865464
Bibliographic data and abstract were imported from PubMed on 13 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.